Moderna (NASDAQ:MRNA) Stock Rating Lowered by The Goldman Sachs Group

Moderna (NASDAQ:MRNA - Get Free Report) was downgraded by investment analysts at The Goldman Sachs Group from a "buy" rating to a "neutral" rating in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. They currently have a $51.00 target price on the stock, down from their prior target price of $99.00. The Goldman Sachs Group's target price suggests a potential upside of 22.85% from the stock's previous close.

A number of other brokerages also recently commented on MRNA. Piper Sandler restated an "overweight" rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. Barclays reduced their price objective on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating for the company in a research note on Friday, November 8th. Needham & Company LLC reissued a "hold" rating on shares of Moderna in a report on Friday, November 8th. Hsbc Global Res raised shares of Moderna from a "hold" rating to a "strong-buy" rating in a report on Monday, November 18th. Finally, Leerink Partners decreased their price target on Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $67.26.

Moderna Stock Down 7.6 %

Shares of Moderna stock traded down $3.43 during trading hours on Wednesday, hitting $41.51. The company had a trading volume of 11,051,780 shares, compared to its average volume of 12,725,583. The company's 50-day moving average is $40.79 and its two-hundred day moving average is $62.18. Moderna has a twelve month low of $31.94 and a twelve month high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company has a market cap of $15.98 billion, a P/E ratio of -7.15 and a beta of 1.60.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period last year, the firm posted ($1.39) earnings per share. Analysts anticipate that Moderna will post -9.27 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company's stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold 2,664 shares of company stock valued at $115,210 over the last quarter. Company insiders own 15.70% of the company's stock.

Institutional Trading of Moderna

A number of hedge funds and other institutional investors have recently modified their holdings of MRNA. Marshall Wace LLP grew its position in shares of Moderna by 295.5% during the 2nd quarter. Marshall Wace LLP now owns 35,200 shares of the company's stock valued at $4,180,000 after buying an additional 26,300 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Moderna by 32.0% during the second quarter. AQR Capital Management LLC now owns 5,083 shares of the company's stock valued at $604,000 after purchasing an additional 1,232 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Moderna by 11.9% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 11,932 shares of the company's stock worth $1,417,000 after purchasing an additional 1,265 shares during the last quarter. Truist Financial Corp boosted its position in Moderna by 7.3% during the 2nd quarter. Truist Financial Corp now owns 18,657 shares of the company's stock valued at $2,216,000 after purchasing an additional 1,275 shares during the period. Finally, Granite Bay Wealth Management LLC bought a new position in Moderna during the 2nd quarter worth $524,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.